Sleep in multiple sclerosis patients treated with interferon beta: an actigraphic study

Area of Science:

• Neurology
• Sleep Medicine
• Immunology

Background:

• Sleep disorders are prevalent in multiple sclerosis (MS) patients.
• Interferon beta (IFN-β), a common MS therapy, may influence sleep patterns.

Purpose of the Study:

• To evaluate and characterize actigraphic sleep patterns in MS patients receiving IFN-β therapy.
• To compare sleep quality and actigraphy data between MS patients and healthy controls.
• To assess the impact of IFN-β administration on sleep architecture.

Main Methods:

• Ten relapsing-remitting MS patients (Expanded Disability Status Scale < 2.5) treated with IFN-β for over 6 months underwent actigraphy.
• Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI).
• A comparison was made between sleep data from drug-free nights and nights following IFN-β administration, with a control group of 10 healthy subjects.

Main Results:

• MS patients showed significantly higher PSQI scores, longer sleep onset latency, reduced sleep efficiency, and more wake episodes compared to controls.
• A significant increase in time in bed was observed after IFN-β administration compared to drug-free nights.

Conclusions:

• The study confirms sleep pattern alterations in MS patients.
• IFN-β may contribute to changes in sleep architecture.
• Actigraphy is a valuable, cost-effective tool for screening sleep disorders in MS patients.